What is the current market valuation of the US male breast-cancer market?

The market valuation was $380.94 Million in 2024. Read More

What is the projected market size for the US male breast-cancer market by 2035?

The market is projected to reach $956.52 Million by 2035. Read More

What is the expected CAGR for the US male breast-cancer market during the forecast period 2025 - 2035?

The expected CAGR is 8.73% during the forecast period. Read More

Which companies are the key players in the US male breast-cancer market?

Key players include Roche, Novartis, Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Eli Lilly and Company, and Johnson & Johnson. Read More

What are the main types of male breast cancer and their market valuations?

Ductal Carcinoma in Situ was valued at $76.19 Million, while Infiltrating Ductal Carcinoma reached $209.51 Million in 2024. Read More

What diagnostic methods are used in the US male breast-cancer market?

Mammography and biopsy methods were valued at $50.0 Million and $70.0 Million, respectively, in 2024. Read More

What are the local treatment options available for male breast cancer?

Local treatments included surgery valued at $150.0 Million and radiation therapy at $230.94 Million in 2024. Read More

What systemic treatment options are available for male breast cancer?

Systemic treatments included chemotherapy valued at $76.19 Million and hormone therapy at $152.38 Million in 2024. Read More

What is the market valuation for targeted therapy in male breast cancer?

Targeted therapy for cancer with BRCA mutations was valued at $190.46 Million in 2024. Read More

How does the market for male breast cancer compare to other cancer types?

The male breast-cancer market appears to be growing steadily, with a projected increase to $956.52 Million by 2035, indicating a robust demand. Read More

US Male Breast Cancer Market

ID: MRFR/Pharma/17391-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Male Breast Cancer Market Research Report By Type (Infiltrating Ductal Carcinoma, Inflammatory Breast Cancer, Paget Disease, Ductal Carcinoma), By Diagnosis (Mammography, Biopsy, Pet Scan, Others) and By Treatment (Local, Systemic) - Growth & Industry Forecast 2025 To 2035

US Male Breast Cancer Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Ductal Carcinoma in Situ
  2. 4.1.2 Paget’s Disease of the Nipple
  3. 4.1.3 Inflammatory Breast Cancer
  4. 4.1.4 Infiltrating Ductal Carcinoma
2. 4.2 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
  1. 4.2.1 Mammography
  2. 4.2.2 Biopsy
  3. 4.2.3 Fine Needle Aspiration Biopsy
  4. 4.2.4 Core Biopsy
  5. 4.2.5 Excisional Biopsy
  6. 4.2.6 PET Scan
  7. 4.2.7 CT Scan
  8. 4.2.8 MRI Scan
  9. 4.2.9 Other Tests
3. 4.3 Food, Beverages & Nutrition, BY Treatment (USD Million)
  1. 4.3.1 Local Treatments
  2. 4.3.2 Systemic Treatments
4. 4.4 Food, Beverages & Nutrition, BY Local Treatments (USD Million)
  1. 4.4.1 Surgery
  2. 4.4.2 Radiation Therapy
5. 4.5 Food, Beverages & Nutrition, BY Surgery (USD Million)
  1. 4.5.1 Mastectomy
  2. 4.5.2 Breast-Conserving Surgery
  3. 4.5.3 Lymph Nodes Biopsy
6. 4.6 Food, Beverages & Nutrition, BY Systemic Treatments (USD Million)
  1. 4.6.1 Chemotherapy
  2. 4.6.2 Hormone Therapy
  3. 4.6.3 Targeted Therapy
7. 4.7 Food, Beverages & Nutrition, BY Chemotherapy (USD Million)
  1. 4.7.1 Adjuvant Therapy
  2. 4.7.2 Neoadjuvant Therapy
8. 4.8 Food, Beverages & Nutrition, BY Hormone Therapy (USD Million)
  1. 4.8.1 Using Drugs
  2. 4.8.2 Orchiectomy (Castration)
9. 4.9 Food, Beverages & Nutrition, BY Targeted Therapy (USD Million)
  1. 4.9.1 For HER2 Positive Breast Cancer
  2. 4.9.2 For Hormone Receptor Positive Breast Cancer
  3. 4.9.3 For Cancer with BRCA Mutations
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY LOCAL TREATMENTS
6. 6.6 US MARKET ANALYSIS BY SURGERY
7. 6.7 US MARKET ANALYSIS BY SYSTEMIC TREATMENTS
8. 6.8 US MARKET ANALYSIS BY CHEMOTHERAPY
9. 6.9 US MARKET ANALYSIS BY HORMONE THERAPY
10. 6.10 US MARKET ANALYSIS BY TARGETED THERAPY
11. 6.11 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
12. 6.12 RESEARCH PROCESS OF MRFR
13. 6.13 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
14. 6.14 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
15. 6.15 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
16. 6.16 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
20. 6.20 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
21. 6.21 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
22. 6.22 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
23. 6.23 FOOD, BEVERAGES & NUTRITION, BY LOCAL TREATMENTS, 2024 (% SHARE)
24. 6.24 FOOD, BEVERAGES & NUTRITION, BY LOCAL TREATMENTS, 2024 TO 2035 (USD Million)
25. 6.25 FOOD, BEVERAGES & NUTRITION, BY SURGERY, 2024 (% SHARE)
26. 6.26 FOOD, BEVERAGES & NUTRITION, BY SURGERY, 2024 TO 2035 (USD Million)
27. 6.27 FOOD, BEVERAGES & NUTRITION, BY SYSTEMIC TREATMENTS, 2024 (% SHARE)
28. 6.28 FOOD, BEVERAGES & NUTRITION, BY SYSTEMIC TREATMENTS, 2024 TO 2035 (USD Million)
29. 6.29 FOOD, BEVERAGES & NUTRITION, BY CHEMOTHERAPY, 2024 (% SHARE)
30. 6.30 FOOD, BEVERAGES & NUTRITION, BY CHEMOTHERAPY, 2024 TO 2035 (USD Million)
31. 6.31 FOOD, BEVERAGES & NUTRITION, BY HORMONE THERAPY, 2024 (% SHARE)
32. 6.32 FOOD, BEVERAGES & NUTRITION, BY HORMONE THERAPY, 2024 TO 2035 (USD Million)
33. 6.33 FOOD, BEVERAGES & NUTRITION, BY TARGETED THERAPY, 2024 (% SHARE)
34. 6.34 FOOD, BEVERAGES & NUTRITION, BY TARGETED THERAPY, 2024 TO 2035 (USD Million)
35. 6.35 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY LOCAL TREATMENTS, 2025-2035 (USD Million)
  5. 7.2.5 BY SURGERY, 2025-2035 (USD Million)
  6. 7.2.6 BY SYSTEMIC TREATMENTS, 2025-2035 (USD Million)
  7. 7.2.7 BY CHEMOTHERAPY, 2025-2035 (USD Million)
  8. 7.2.8 BY HORMONE THERAPY, 2025-2035 (USD Million)
  9. 7.2.9 BY TARGETED THERAPY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Type (USD Million, 2025-2035)

Ductal Carcinoma in Situ
Paget’s Disease of the Nipple
Inflammatory Breast Cancer
Infiltrating Ductal Carcinoma

Food, Beverages & Nutrition By Diagnosis (USD Million, 2025-2035)

Mammography
Biopsy
Fine Needle Aspiration Biopsy
Core Biopsy
Excisional Biopsy
PET Scan
CT Scan
MRI Scan
Other Tests

Food, Beverages & Nutrition By Treatment (USD Million, 2025-2035)

Local Treatments
Systemic Treatments

Food, Beverages & Nutrition By Local Treatments (USD Million, 2025-2035)

Surgery
Radiation Therapy

Food, Beverages & Nutrition By Surgery (USD Million, 2025-2035)

Mastectomy
Breast-Conserving Surgery
Lymph Nodes Biopsy

Food, Beverages & Nutrition By Systemic Treatments (USD Million, 2025-2035)

Chemotherapy
Hormone Therapy
Targeted Therapy

Food, Beverages & Nutrition By Chemotherapy (USD Million, 2025-2035)

Adjuvant Therapy
Neoadjuvant Therapy

Food, Beverages & Nutrition By Hormone Therapy (USD Million, 2025-2035)

Using Drugs
Orchiectomy (Castration)

Food, Beverages & Nutrition By Targeted Therapy (USD Million, 2025-2035)

For HER2 Positive Breast Cancer
For Hormone Receptor Positive Breast Cancer
For Cancer with BRCA Mutations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”